OVID THERAPEUTICS INC.

Analyst Reco. Ovid Therapeutics Inc.

Equities

OVID

US6904691010

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
0.7692 ^USD	+5.89%		-1.38%	-76.11%

06-18	Oppenheimer Downgrades Ovid Therapeutics to Market Perform	MT
06-18	B. Riley Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Oppenheimer Downgrades Ovid Therapeutics to Market Perform	06-18	MT
B. Riley Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating	06-18	MT
BTIG Adjusts Price Target on Ovid Therapeutics to $5 From $11, Maintains Buy Rating	06-18	MT
HC Wainwright Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating	06-18	MT
Citigroup Adjusts Price Target on Ovid Therapeutics to $1.20 From $3.50, Maintains Neutral Rating	06-18	MT
Wedbush Lowers PT on Ovid Therapeutics to $4 From $8 After Soticlestat Missed Endpoints in Phase 3 Studies; Maintains Outperform Rating	06-17	MT
B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target	04-30	MT
HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target	04-29	MT
BTIG Initiates Ovid Therapeutics With Buy Rating, Price Target is $11	12-21	MT
Oppenheimer Initiates Coverage on Ovid Therapeutics With Outperform Rating, $8 Price Target	13/10/23	MT
JonesTrading Initiates Ovid Therapeutics at Buy With $6 Price Target	14/06/23	MT
Citigroup Adjusts Ovid Therapeutics' Price Target to $2.40 from $4, Keeps Neutral Rating	20/05/22	MT
OVID THERAPEUTICS : Citigroup Adjusts Ovid Therapeutics' Price Target to $4 from $4.50, Keeps Neutral Rating	25/08/21	MT
OVID THERAPEUTICS : Cantor Fitzgerald Downgrades Ovid Therapeutics to Neutral from Overweight, Adjusts PT to $4 from $8	20/04/21	MT
OVID THERAPEUTICS : RBC Cuts Price Target on Ovid Therapeutics to $4 From $5, Maintains Rating at Sector Perform, Speculative Risk	20/04/21	MT
OVID THERAPEUTICS : Ladenburg Thalmann Adjusts Price Target on Ovid Therapeutics to $7 From $21, Maintains Buy Rating	02/12/20	MT
OVID THERAPEUTICS : RBC Capital Adjusts Ovid Therapeutics PT to $5 From $17, Maintains Outperform - Speculative Risk Rating	02/12/20	MT
OVID THERAPEUTICS : Citigroup Downgrades Ovid Therapeutics to Neutral From Buy, Adjusts Price Target to $4 From $10	02/12/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer